Inhalation-grade lactose, aerosol propellants, and other excipients for inhalation and intranasal formulations
Orbia Fluor & Energy Materials’ (FEM) pharma business is advancing the transition to more sustainable medical propellants for metered‑dose inhalers (MDIs) with Zephex® 152a; a low‑GWP medical propellant for use in MDIs. Compared with traditional propellants, it significantly reduces the associated GWP by around 90%, while preserving established performance and patient experience. Orbia F&EM is investing in large-scale manufacturing capacity and supply reliability to support global demand. Supported by over 30 years of expertise with the Zephex® brand, Zephex® 152a is positioned to help the respiratory industry meet sustainability goals without compromising patient experience.
Powered by some of the brightest minds in our industry, Solstice Advanced Materials is a leading specialty materials company that advances science to achieve smarter outcomes with high-performance solutions across healthcare, semiconductor materials, protective fibers, and more. Solstice’s medical propellant HFO-1234ze(E), GMP uses Hydrofluoroolefin (HFO) technology, a sustainable alternative to HFAs in MDIs. With an ultra-low GWP, HFO-1234ze(E) is a breakthrough medical propellant currently in clinical development for pMDIs with the ability to reduce greenhouse gas emissions of propellant by up to 99.9% versus the current inhaler propellant.
Would you like to list your company in this section or upgrade your existing listing? For information about supplier listing options, click here.
